Urotensin-II and the cardiovascular system – the importance of developing modulators

Bibliography

• COULOUARN Y, LIHRMANN I, JEGOU S et al.: Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin gene in motorneurons of the spinal cord. Proc. Natl. Acad. ScL USA (1998) 95:15803–15808.
   PubMed Web of Science ®Google Scholar
• AMES RS, SARAU HM, CHAMBERS JK et al.: Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature (1999) 401:282–286.
   PubMed Web of Science ®Google Scholar
• ••Landmark paper renewing interest in U-II.
   Google Scholar
• ELSHOURBAGY NA, DOUGLAS SA, SHABON U et al.: Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-couple receptors from the mouse and monkey. Br. Pharmacol. (2002) 36:9–22.
   Web of Science ®Google Scholar
• LIU Q, PONG SS, ZENG Z et al.: Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14. Biochem. Biophys. Res. Commun. (1999) 266:174–178.
   PubMed Web of Science ®Google Scholar
• ZILTENER P, MUELLER C, HAENIG B,SCHERZ MW, NAYLER 0: Urotensin II mediates ERK1/2 phosphorylation and proliferation in GPR14-transfected cell lines. j Recept. Signal Bansduct. Res. (2002) 22:155–168.
   PubMed Web of Science ®Google Scholar
• MORI M, SUGO T, ABE M et al.: Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14). Biochem. Biophys. Res. Commun. (1999) 265:123–129.
   PubMed Web of Science ®Google Scholar
• MAGUIRE JJ, KUC RE, DAVENPORT AP: Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. Br. Pharmacol. (2000) 131:441–446.
   PubMed Web of Science ®Google Scholar
• •First description of U-II causing the contriction of human blood vessels.
   Google Scholar
• DOUGLAS SA, SULPHIZIO AC, PIERCY V et al.: Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, pig, marmoset and cynomolgus monkeys. Br. Pharmacol. (2000) 131:1262–1274.
   PubMed Web of Science ®Google Scholar
• •Important characterisation of the species differences in the vascular effects of U-II.
   Google Scholar
• BOTTRILL FE, DOUGLAS SA, HILEY CR, WHITE R: Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br. Pharmacol. (2000) 130:1865–1870.
   PubMed Web of Science ®Google Scholar
• KATANO Y, ISHIHATA A, AITAT, OGAKI T, HORIE T: Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries. Ear. Pharmacol. (2000) 402:R5–R7.
   PubMed Web of Science ®Google Scholar
• GRAY GA, JONES MR, SHARIF I: Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric synthase and cyclooxygenase inhibition. Life ScL (2001) 69:175–180.
   PubMed Web of Science ®Google Scholar
• SAUZEAU V, LE MELLIONNEC E, BERTOGLIO J et al.: Human urotensin II-induced contraction and arterial smooth muscle proliferation are mediated by RhoA and Rho-kinase. Circ. Res. (2001) 88:1102–1104.
   PubMed Web of Science ®Google Scholar
• ROSSOWSKI WJ, CHENG BL, TAYLOR JE, DATTA R, COY DH: Human urotensin II-induced aorta rings contractions are mediated be protein kinase C, tyrosine kinases and Rho-kinase inhibition by somatostatin receptor antagonists. Ear. Pharmacol. (2002) 438:159–170
   PubMed Web of Science ®Google Scholar
• SAETRUM OPGAARD 0, NOTHACKER E, EHLERT FJ, KRAUSE DN: Human urotensin II mediated vasoconstriction via an increase in inositol phosphates. Ear. Pharmacol. (2000) 13:265–271.
   Web of Science ®Google Scholar
• WATANABE T, PAKALA R, KATAGIRI T, BENEDICT CR: Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation (2001) 104:16–18.
   PubMed Web of Science ®Google Scholar
• BEHM DJ, HARRISON SM, AO Z et al.:Deletion of the UT receptor gene results in the selective loss of urotensin-II contractile activity in aortae isolated from UT receptor knockout mice. Br. Pharmacol. (2003) 139:464–472.
   PubMed Web of Science ®Google Scholar
• MacLEAN MR, ALEXANDER D, STIRRAT A et al.: Contractile responses to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br. Pharmacol. (2000) 130:201–204.
   PubMed Web of Science ®Google Scholar
• STIRRAT A, GALLAGHER M, DOUGLAS GA et al.: Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am. j Physiol. Heart Circ. Physiol. (2001) 280:H925–H928.
   PubMed Web of Science ®Google Scholar
• •Characterisation of human vasodilator responses to U-II.
   Google Scholar
• ZHANG AY, CHEN YE ZHANG DX et al.: Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am. j Physiol. Renal Physiol. (2003) 285:F792–F798.
   Google Scholar
• HILLIER C, BERRY C, PETRIE M et al.:Effects of urotensin II in human arteries and veins of varying caliber. Circulation (2001) 103:1378–1381.
   PubMed Web of Science ®Google Scholar
• PAYSANT J, RUPIN A, SIMONET S, FABIANI JN, VERBEUREN TJ: Comparison of the contractile responses of human coronary bypass grafts and monkey arteries to human urotensin-II. Fundam. Clin. Pharmacol. (2001) 15:227–231.
   PubMed Web of Science ®Google Scholar
• RUSSELL FD, MOLENAAR P, O'BRIEN DM: Cardiostimulant effects of urotensin-II in human heart M vitro. Br. Pharmacol. (2001) 132:5–9.
   PubMed Web of Science ®Google Scholar
• •Early characterisation of the effects of U-II on the human heart.
   Google Scholar
• TZANIDIS A, HANNAN RD, THOMAS WG et al.: Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ. Res. (2003) 93:246–253.
   PubMed Web of Science ®Google Scholar
• ZOU Y, NAGAI R, YAMAZAKI T: Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats. FEBS Lett. (2001) 508:57–60.
   PubMed Web of Science ®Google Scholar
• ZHU YZ, WANG ZJ, ZHU YC et al.: Urotensin II causes fatal circulatory collapse in anaesthesized cynomolgus monkeys in vivo: a 'vasoconstrictor' with a unique hemodynamic profile. Am. I Physiol. Heart Circ. Physiol. (2004) 286(3):H830–H836.
   PubMed Web of Science ®Google Scholar
• AFFOLTER JT, NEWBY DE, WILKINSON IB et al.: No effect on central or peripheral blood pressure of systemic urotensin II infusion in humans. Br. Clin. Pharmacol. (2002) 54:617–621.
   PubMed Web of Science ®Google Scholar
• •Important study demonstrating the lack of effects of infusing U-II in humans.
   Google Scholar
• BOHM F, PERNOW J: Urotensin II evokes potent vasoconstriction in humans in vivo. Br. Pharmacol. (2002) 135:25–27.
   PubMed Web of Science ®Google Scholar
• WILKINSON IB, AFFOLTER JT, DE HAAS SL et al.: High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man. Cardiovasc. Res. (2002) 53:341–347.
   Google Scholar
• GIBSON A, WALLACE P, BERN HA: Cardiovascular effects of urotensin II in anesthetized and pithed rats. Gen. Comp. Endocrinol (1986) 64:435–439.
   PubMed Web of Science ®Google Scholar
• GARDINER SM, MARCH JE, KEMP PA,DAVENPORT AP, BENNETT T: Depressor and regionally-selective vasodilator effects of human and urotensin II in conscious rats. ELI Pharmacol (2001) 132:1625–1629.
   Web of Science ®Google Scholar
• ABDELRAHMAN AM, PANG CC: Involvement of the nitric wdde/L-arinine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats. Life Sci. (2002) 71:819–825.
   PubMed Web of Science ®Google Scholar
• LU Y, ZHOU CJ, HUANG DW, TANG CS: Cardiovascular effects of urotensin II in different brain areas. Peptides (2002) 23:1631–1635.
   PubMed Web of Science ®Google Scholar
• UN Y, TSUCHIHASHI T, MATSUMURA K, ABE I, IIDA M: Central cardiovascular action of urotensin II in conscious rats. J. Hypertens. (2003) 21:159–165.
   PubMed Web of Science ®Google Scholar
• WATSON AM, LAMBERT GW, SMITH KJ, MAY CN: Urotensin II acts centrally to increase epinephrine and ACTH releases and cause inotropic and chronotropic actions. Hypertension (2003) 42:373–379.
   PubMed Web of Science ®Google Scholar
• KATUGAMPOLA SD, KUC RE, MAGUIRE JJ, DAVENPORT AP: G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors. Clin. Sci. (2002) 103\(Suppl. 48):1715–1755.
   Google Scholar
• DOUGLAS SA, TAYARA L, OHLSTEIN EH, HALAWA N, GIAID A: Congestive heart failure and expression of myocardial urotensin II. Lancet (2002) 359:1990–1997.
   PubMed Web of Science ®Google Scholar
• RICHARDS AM, NICHOLLS MG, LAINCHBURY JG, FISHER S, YANDLE TG: Plasma urotensin II in heart failure. Lancet (2002) 360:545–546.
   PubMed Web of Science ®Google Scholar
• RUSSELL FD, MEYERS D, GALBRAITH AJ et al.: Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure. Am. j Physiol Heart Circ. Physiol (2003) 285:H1576–H1581.
   PubMed Web of Science ®Google Scholar
• DSCHIETZIG T, BARTSCH C, PREGLA R et al.: Plasma levels and cardiovascular gene expression on urotensin II in human heart failure. Regal Pept. (2002) 110:33–38.
   PubMed Web of Science ®Google Scholar
• THOMPSON JP, WATT P, SANGHAVI S,STRUPISH JW, LAMBERT DG: A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anaesth. Analg. (2003) 97:1501–1503.
   PubMed Web of Science ®Google Scholar
• MATSUSHITA M, SHICHIRI M, IMAI T et al.: Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J. Hypertens. (2001) 19:2185–2190.
   PubMed Web of Science ®Google Scholar
• LIN Y, TSUCHIHASHI T, MATSUMURA K et al.: Central cardiovascular action of urotensin II in spontaneously hypertensive rats. Hypertens. Res. (2003) 26:839–845.
   PubMed Web of Science ®Google Scholar
• HELLER J, SCHEPKE M, NEEF M et al: Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension. J. Hepatol. (2002) 37:767–772.
   PubMed Web of Science ®Google Scholar
• TOTSUNE K, TAKAHASHI K, ARIHARA Z et al.: Increased plasma urotensin II levels in patients with diabetes mellitus. Clin. Sci. (2003) 104:1–5.
   PubMed Web of Science ®Google Scholar
• ELSHOURBAGY NA, DOUGLAS SA, SHABON U et al.: Molecular and pharmacological characterization of genes encoding urotensin-II peptides and their cognate G-protein-coupled receptors from the mouse and monkey. Br. J. Pharmacol (2002) 136:9–22.
   PubMed Web of Science ®Google Scholar
• LABARRERE P, CHATENET C, LEPRINCE J et al: Structure-activity relationships of human urotensin II and related analogues on rat aortic ring contraction. I Enzyme Inhib. Med. Chem. (2003) 18:77–88.
   PubMed Web of Science ®Google Scholar
• GRIECO P, CAROTENUTO A, CAMPIGLIA P et al.: A new, potent urotensin II receptor peptide agonist containing Pen residue in the disulfide bridge. j. Med. Chem. (2002) 45:4391–4394.
   PubMed Web of Science ®Google Scholar
• CAMARDA V, GUERRINI R, KOSTENIS E et al.: A new ligand for the urotensin II receptor. Br. J. Pharmacol (2002) 137:311–314.
   PubMed Web of Science ®Google Scholar
• GRIECO P, CAROTENUTO A, PATACCHINI R et al.: Design, synthesis, conformational analysis, and biological study of urotensin-II lactam analogues. Bioorg. Med. Chem. (2002) 10:3731–3739.
   PubMed Web of Science ®Google Scholar
• BRKOVIC A, HATTENBERGER A, KOSTENIS E et al.: Functional and binding characterizations of urotensin II-related peptides in human and rat urotensin II-receptor assay. J. Pharmacol Exp. Thec (2003) 306:1200–1209.
   PubMed Web of Science ®Google Scholar
• CROSTON GE, OLSSON R, CURRIER EA et al.: Discovery of the first nonpeptide agonist of the GPR14/ urotensin-II receptor: 3-(4-chloropheny1)-3-(2-dimethylamino) ethyl) isochroman- 1-one (AC-7954).J Med. Chem. (2002) 45:4950–4953.
   Google Scholar
• •First description of a non-peptide UT receptor agonist.
   Google Scholar
• BEHM DJ, HEROLD CL, OHLSTEIN EH et al.: Pharmacological characterization of SB-710411 (Cpa-c[D-Cys-Pal-D-Trp-Lys-Val-Cys]-Cpa-amide), a novel peptidic urotensin-II receptor antagonist. Br. J. Pharmacol (2002) 137:449–458.
   PubMed Web of Science ®Google Scholar
• HEROLD CL, BEHM DJ, BUCKLEY PT et al.: The neuromedin B receptor antagonist, BIM-23127, is a potent antagonist at human and rat urotensin-II receptors. Br. .1. Pharmacol (2003) 139:203–207.
   Google Scholar
• PATACCHINI R, SANTICIOLI P, GIULIANI S et al.: Urantide: an ultrapotent urotensin II antagonist peptide in the rat aorta. Br. J. Pharmacol (2003) 140:1155–1158.
   PubMed Web of Science ®Google Scholar
• FLOHR S, KURZ M, KOSTENIS E et al: Identification of nonpeptidic urotensin II receptor antagonists by virtual screening based on a pharmacophore model derived from structure-activity relationships and nuclear magnetic resonance studies on urotensin II. J. Med. Chem. (2002) 45:1799–1805.
   PubMed Web of Science ®Google Scholar
• •Important description of a nonpeptide UT receptor antagonist.
   Google Scholar
• SUGO T, MURAKAMI Y, SHIMOMURA Y et al.: Identification of urotensin II-related peptide as the urotensin II immunoreactive molecule in the rat brain. Biochem. Biophys. Res. Commun. (2003) 310:860-868. Affiliation
   Google Scholar